WHF Roadmap on Single Pill Combination Therapies
By: Enrico G. Ferro, Gautam Satheesh, José Castellano, Albertino Damasceno, Okeoma Erojikwe, Mark Huffman, Vilma Irazola, Philip Joseph, Fernando Lanas, Elijah Ogola, Pedro Ordunez, Pablo Perel, Daniel Pineiro, Izabela Uchmanowicz, Orly Vardeny, Ruth Webster, Habib Gamra, Thomas Gaziano and Adrianna Murphy
References
- Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The Heart of the World. Glob Heart. 2024;19(1):11. DOI: 10.5334/gh.1288
- Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Bmj. 2003;326(7404):1419. DOI: 10.1136/bmj.326.7404.1419
- Katzmann JL, Sorio-Vilela F, Dornstauder E, Fraas U, Smieszek T, Zappacosta S, et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. 2022;111(3):243–52. DOI: 10.1007/s00392-020-01740-8
- Banach M, Jaiswal V, Ang SP, Sawhney A, Deb N, Amarenco P, et al. Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis. Mayo Clin Proc. 2025. DOI: 10.1016/j.mayocp.2025.01.018
- Campbell NRC. A step in the global effort to control hypertension: Fixed dose combination antihypertensive drugs. J Clin Hypertens (Greenwich). 2019.21(9):1426–8. DOI: 10.1111/jch.13683
- Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125–36. DOI: 10.5114/aoms.2018.77561
- Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021–31. DOI: 10.1056/NEJMoa1600176
- Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–83. DOI: 10.1016/S0140-6736(19)31791-X
- Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216–28. DOI: 10.1056/NEJMoa2028220
- Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967–77. DOI: 10.1056/NEJMoa2208275
- Agarwal A, Mehta PM, Jacobson T, Shah NS, Ye J, Zhu J, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med. 2024;30(4):1199–209. DOI: 10.1038/s41591-024-02896-w
- Agarwal A, Mehta PM, Jacobson T, Shah NS, Ye J, Zhu J, et al. Author Correction: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med. 2024;30(8):2371. DOI: 10.1038/s41591-024-03128-x
- Gaziano TA, Pandya A, Sy S, Jardim TV, Ogden JM, Rodgers A, et al. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019;214:77–87. DOI: 10.1016/j.ahj.2019.04.020
- Jahangiri R, Rezapour A, Malekzadeh R, Olyaeemanesh A, Roshandel G, Motevalian SA. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review. PLoS One. 2022;17(7):
e0271908 . DOI: 10.1371/journal.pone.0271908 - Lamy A, Tong W, Joseph P, Gao P, Huffman MD, Roshandel G, et al. Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis. EClinicalMedicine. 2024;73:102651. DOI: 10.1016/j.eclinm.2024.102651
- O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761–75. DOI: 10.1016/S0140-6736(16)30506-2
- Agarwal A, Yancy CW, Huffman MD. Improving Care for Heart Failure With Reduced Ejection Fraction-A Potential Polypill-Based Strategy. Jama. 2020;324(22):2259–60. DOI: 10.1001/jama.2020.21395
- Pandey A, Keshvani N, Wang TJ. Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction? Circulation. 2022;146(4):276–8. DOI: 10.1161/CIRCULATIONAHA.122.059661
- Vijay A, Tay WT, Teng TK, Teramoto K, Tromp J, Ouwerkerk W, et al. Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis. Glob Heart. 2023;18(1):33. DOI: 10.5334/gh.1215
- Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. Jama. 2013;310(9):918–29. DOI: 10.1001/jama.2013.277064
- Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Bmj. 2014;348:g3318. DOI: 10.1136/bmj.g3318
- Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920–30. DOI: 10.1177/2047487314530382
- Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133–46. DOI: 10.1016/S0140-6736(21)01827-4
- Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. 2016;205:147–56. DOI: 10.1016/j.ijcard.2015.12.015
- Sarfo FS, Voeks J, Adamu S, Agyei BA, Agbenorku M, Adu-Darko N, et al. A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial. Lancet Glob Health. 2023;11(10):e1619–e28. DOI: 10.1016/S2214-109X(23)00347-9
- Watkins DA, Pickersgill SJ, Flood D, Gaziano TA, Huffman MD, Islam S, et al. Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023–2050: A Modeling Study. J Am Coll Cardiol. 2025;86(3):149–61. DOI: 10.1016/j.jacc.2025.04.043
- Mohamed MG, Osman M, Kheiri B, Saleem M, Lacasse A, Alkhouli M. Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2022;360:91–8. DOI: 10.1016/j.ijcard.2022.04.085
- Memon RA, Raveena Bai B, Simran F, Kumari M, Aisha F, Sai Kiran K, et al. Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Cureus. 2023;15(1):
e34134 . DOI: 10.7759/cureus.34134 - Lopez-Lopez JP, Gonzalez AM, Lanza P, Lopez-Jaramillo P. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. Vasc Health Risk Manag. 2023;19:605–15. DOI: 10.2147/VHRM.S421024
- The Lancet. Polypills: an essential medicine for cardiovascular disease. Lancet. 2017;389(10073):984. DOI: 10.1016/S0140-6736(17)30695-5
- Frost LJ, Reich MR. Creating access to health technologies in poor countries. Health Aff (Millwood). 2009.28(4):962–73. DOI: 10.1377/hlthaff.28.4.962
- Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health Policy and Planning. 2012;28(7):692–704. DOI: 10.1093/heapol/czs108
- Vledder M, Friedman J, Sjöblom M, Brown T, Yadav P. Improving Supply Chain for Essential Drugs in Low-Income Countries: Results from a Large Scale Randomized Experiment in Zambia. Health Syst Reform. 2019;5(2):158–77. DOI: 10.1080/23288604.2019.1596050
- Organization WH. Antiretroviral medicines in low- and middle-income countries: forecasts of global and regional demand for 2020–2024; 2022.
- Satheesh G, Gyawali B, Sun MFC, Huffman MD, Banerjee A, Perel P, et al. A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries. Glob Heart. 2024;19(1):56. DOI: 10.5334/gh.1335
- DRL’s Red Heart Pill off R&D shelves. The New Indian Express. 2013; 15 February 2013.
- Liu H, Huffman MD, Trieu K. The role of contextualisation in enhancing non-communicable disease programmes and policy implementation to achieve health for all. Health Res Policy Syst. 2020;18(1):38. DOI: 10.1186/s12961-020-00553-5
- Rodgers A, Smith R. The polypill and medicines access: two decades and counting. Bmj. 2023;382:1847. DOI: 10.1136/bmj.p1847
- Mitra A, Wu Y. Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. Aaps j. 2012;14(3):646–55. DOI: 10.1208/s12248-012-9378-x
- (CDER) USDoHaHSFaDACfDEaR. Hypertension: Developing Fixed-Combination Drug Products for Treatment. Guidance for Industry.
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm2018 . - European Medicines Agency. Guideline on clinical development of fixed combination medicinal products. 2017.
- Ren W, Zhao Y, Zhong H, Fu X, Wu J. Exploring the Optimal Allocation Decision-Making of Expenditure Budget in Hospitals Under Multi-Objective Constraints: Evidence from Urban Public Hospitals, China. SAGE Open. 2021;11(4):21582440211058191. DOI: 10.1177/21582440211058191
- Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Glob Health. 2020;5(11). DOI: 10.1136/bmjgh-2020-002640
- Murphy A, Palafox B, Walli-Attaei M, Powell-Jackson T, Rangarajan S, Alhabib KF, et al. The household economic burden of non-communicable diseases in 18 countries. BMJ Glob Health. 2020;5(2):
e002040 . DOI: 10.1136/bmjgh-2019-002040 - Negi S, Neupane D, Sahoo SK, Mahajan T, Swaroop K, Moran AE, et al. Prices of combination medicines and single-molecule antihypertensive medicines in India’s private health care sector. J Clin Hypertens (Greenwich). 2021;23(4):738–43. DOI: 10.1111/jch.14143
- Becerra V, Gracia A, Desai K, Abogunrin S, Brand S, Chapman R, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015;5(5):
e007111 . DOI: 10.1136/bmjopen-2014-007111 - Lin JK, Moran AE, Bibbins-Domingo K, Falase B, Pedroza Tobias A, Mandke CN, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. Lancet Glob Health. 2019;7(10):e1346–e58. DOI: 10.1016/S2214-109X(19)30339-0
- Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. PLoS One. 2015;10(10):
e0140708 . DOI: 10.1371/journal.pone.0140708 - Beall RF, Schwalm JD, Huffman MD, McCready T, Yusuf S, Attaran A. Could patents interfere with the development of a cardiovascular polypill? J Transl Med. 2016;14(1):242. DOI: 10.1186/s12967-016-0997-3
- Marklund M, Mattingly Ii TJ, Sahoo SK, Kaur P, Moran AE, Appel LJ, et al. Effects of medication procurement reforms and extended prescription duration on medication coverage for hypertension in India’s public health system: a modelling study. BMJ Public Health. 2025;3(1):
e001044 . DOI: 10.1136/bmjph-2024-001044 - Bazargani YT, Ewen M, de Boer A, Leufkens HG, Mantel-Teeuwisse AK. Essential medicines are more available than other medicines around the globe. PLoS One. 2014;9(2):
e87576 . DOI: 10.1371/journal.pone.0087576 - Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. DOI: 10.1097/HJH.0000000000003480
- Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(38):3720–826. DOI: 10.1093/eurheartj/ehad191
- Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. J Am Heart Assoc. 2020;9(9):
e015302 . DOI: 10.1161/JAHA.119.015302 - Liu H, Massi L, Laba TL, Peiris D, Usherwood T, Patel A, et al. Patients’ and providers’ perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial. Circ Cardiovasc Qual Outcomes. 2015;8(3):301–8. DOI: 10.1161/CIRCOUTCOMES.115.001483
- Salam A, Praveen D, Patel A, Tewari A, Webster R. Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study. Glob Heart. 2019;14(3):303–10. DOI: 10.1016/j.gheart.2019.07.002
- Lewis PJ, Tully MP. Uncomfortable prescribing decisions in hospitals: the impact of teamwork. J R Soc Med. 2009;102(11):481–8. DOI: 10.1258/jrsm.2009.090150
- Brax H, Fadlallah R, Al-Khaled L, Kahale LA, Nas H, El-Jardali F, et al. Association between physicians’ interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. PLoS One. 2017;12(4):
e0175493 . - Virdee SK, Greenfield SM, Fletcher K, McManus RJ, Hobbs FDR, Mant J. Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open. 2013;3(3):
e002498 . DOI: 10.1136/bmjopen-2012-002498 - O’Hagan E, McIntyre D, Nguyen T, Tan KM, Hanlon P, Siddiqui M, et al. A Cross-Sectional Survey of Fixed-Dose Combination Antihypertensive Medicine Prescribing in Twenty-Four Countries, Including Qualitative Insights. Global Heart. 2024. DOI: 10.5334/gh.1353
- Giron N, Lim C, Vallini J, Hallar K. Moving toward improved access to medicines and health technologies for cardiovascular disease. Rev Panam Salud Publica. 2023;47:
e93 . DOI: 10.26633/RPSP.2023.93 - Rodgers A, Satheesh G, Murphy A. The Potential of Single Pill Combinations. J Am Coll Cardiol. 2025;86(3):162–4. DOI: 10.1016/j.jacc.2025.06.006
DOI: https://doi.org/10.5334/gh.1457 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jul 25, 2025
Accepted on: Jul 30, 2025
Published on: Aug 29, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2025 Enrico G. Ferro, Gautam Satheesh, José Castellano, Albertino Damasceno, Okeoma Erojikwe, Mark Huffman, Vilma Irazola, Philip Joseph, Fernando Lanas, Elijah Ogola, Pedro Ordunez, Pablo Perel, Daniel Pineiro, Izabela Uchmanowicz, Orly Vardeny, Ruth Webster, Habib Gamra, Thomas Gaziano, Adrianna Murphy, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.